Company Description
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.
Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 25, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 907 |
| CEO | Thomas William Burns |
Contact Details
Address: 1 Glaukos Way Aliso Viejo, California 92656 United States | |
| Phone | 949-367-9600 |
| Website | glaukos.com |
Stock Details
| Ticker Symbol | GKOS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001192448 |
| CUSIP Number | 377322102 |
| ISIN Number | US3773221029 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas William Burns | Chairman and Chief Executive Officer |
| Joseph E. Gilliam | President and Chief Operating Officer |
| Alex R. Thurman | Senior Vice President and Chief Financial Officer |
| Chris M. Calcaterra | Executive Vice President of Global Commercial Operations |
| Dr. Tomas Navratil Ph.D. | Chief Development Officer |
| Dr. Mory Gharib Ph.D. | Co-Founder |
| Christopher William Lewis | Vice President of Investor Relations and Corporate Affairs |
| Diana A. Scherer | Vice President of Compliance and Deputy General Counsel |
| Michele M. Allegretto | Senior Vice President of Human Resources |
| Jane E. Rady | Senior Vice President of Corporate Strategy and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | ARS | Filing |
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2024 | 144 | Filing |
| Apr 8, 2024 | 144 | Filing |
| Apr 5, 2024 | 144 | Filing |
| Apr 5, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |